glp 1 trump administration drug price deal: Burning questions after Lilly, Novo agreement Trump Administration Announces New Voluntary
Description
[DOI] [PMC free article] [PubMed] [Google Scholar] 82.Dickson S.L., Shirazi R.H., Hansson C., Bergquist F., Nissbrandt H., Skibicka K.P
Retatrutide (also written as LY3437943 ) is an investigational triple agonist studied for obesity and other metabolic indications
doi: 10.1093/ndt/gfaa380
In a Monday interview with CNBC's Jim Cramer, Novo Nordisk CEO Mike Doustdar suggested the new pill format of the pharmaceutical giant's weight loss drug will allow more people to use the medicine which had previously been available only as an injectable
Importantly, the analysis excluded patients using the drugs for type 2 diabetes, for which GLP-1 medicines were originally developed
